{"schema_version":"secwatch.filing_event.v1","accession":"0001553350-25-000111","form_type":"8-K","ticker":"PKTX","cik":"0001128189","company_name":"ProtoKinetix, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.852320+00:00","generated_at":"2026-05-16T17:32:30.489412+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"ProtoKinetix CEO updates on founder Clarence Smith's passing and AAGP molecule strategy","bullets":["CEO Guzzetta acknowledges sudden passing of longtime leader Clarence Smith and commitment to his vision.","Company continues development of first-in-class synthetic glycopeptide AAGP (PKX-001) for cell protection and inflammation control.","Global patent portfolio covers US, Europe, UK, Asia; outreach to pharma firms for Type 1 Diabetes, cell therapy, dry-eye, and topical applications.","No financial or operational metrics provided; update is a stockholder letter with no specific milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001553350-25-000111","json":"https://secwatch.observer/filing/0001553350-25-000111.json","markdown":"https://secwatch.observer/filing/0001553350-25-000111.md","text":"https://secwatch.observer/filing/0001553350-25-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1128189/000155335025000111/0001553350-25-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1128189/000155335025000111/pktx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:32:30.489412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}